Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity

Jun 22 2012

Related Content

Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment

Jul 11 2011

Patent Power: Roche Concedes Case Over Amgen's EPO

Dec 22 2009

Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow

Dec 05 2011

Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar

Apr 10 2012

Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier

Oct 01 2010

AMAG Pharmaceuticals: Enough Irons In The Fire?

May 01 2010

Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen

Aug 02 2010

Related Companies

Abbott

Reata Pharmaceuticals, Inc.

Affymax, Inc.

Takeda Pharmaceutical Co. Ltd.

Amgen, Inc.

Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co., Ltd.

AMAG Pharmaceuticals Inc.

Action Pharma A/S

Johnson & Johnson

Case Western Reserve University

KAI Pharmaceuticals

KAI Pharmaceuticals

Sanofi

Akebia Therapeutics, Inc.

FibroGen, Inc.

Astellas Pharma, Inc.

Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

National Institutes of Health

US Department of Health and Human Services

Roche Holding AG

Hospira, Inc.

Additional Topics

Pricing Strategies Launches Reimbursement Government Payers BioPharmaceutical

More from Archive

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window